Skip to main content

Use of tacrine hydrochloride (Cognex®) in private practice

Buy Article:

$51.00 plus tax (Refund Policy)


Before administering tacrine hydrochloride (Cognex®), an examination is conducted that includes a medical history, neurological examination, laboratory studies, EEG, CT or MRI, and sometimes lumbar puncture. Much consideration by physicians, patients, and caregivers goes into the decision to prescribe Cognex®. Aside from a diagnosis of mild to moderate Alzheimer's disease, the patient must be in good health. Patient and caregivers must accept the need for weekly ALT measurements for at least the first 18 weeks of treatment, and for periodic office evaluations. Many of our patients who have received Cognex® show considerable improvement in overall sense of well‐being, affect, and the abilities to converse and participate in daily activities. The most common adverse effects in our patients are nausea, vomiting, and gastrointestinal upset. In our experience, administration of Cognex® extends the time that patients with AD can function in a home environment. This approach often represents a cost savings to the patient's family.

Document Type: Original Article


Affiliations: Ocala, Florida, USA

Publication date: 1996-04-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more